Fundamental Analysis of Corcept Therapeutics Inc. - Growth / Value Index


CORT - Valuation Highlights

Valuation Analysis

   Tremendous increasing in Book Value last 3 year
   Tsr Value Index - Very Poor Score of 6.25
   Price to Book Ratio of 6.74 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 29.67 38.52 -1.68 %
Price to Book 7.06 6.95 -12.14 % 6.32
Price to Sales 6.65 7.82 -20.78 %
Enterprise Value to EBITDA Multiple 25.63 36.06 10.53 %


CORT - Profitability Highlights

Profitability Analysis

   Excellent Net Margin for last 3 years
   Company Earning excess return
   During the past twelve months, the company has given a strong Return On Equity of 23.79%
   All key Trailing Twelve Months Margin growing by 15 %
   Good Return On Capital Employed of 18.04
   Good Net Margin of 22.42% is achieved by the company
   Very Low Dividend Yield of 0.310 %
   Low Earning Yield of 3.53 %
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 23.79 18.04 -10.64 % 5.02
Return On Asset 19.48 14.70 -15.31 % 4.19
Net Profit Margin 22.42 20.31 -19.43 % 18.74
Operating Profit Margin 23.29 21.80 -22.22 % 20.09
EBITDA Margin 23.43 20.86 -29.94 % 20.18


Highlights
Market Cap3279.53 M
Enterprise Value3144.13 M
Price/Book TTM7.06
Outstanding Share104112 K
Float/ Outstanding Share81.64%
Dividend Yield0.310 %
Share Holding
Guru Numbers
Price/Graham No3.03
Peter Lynch Ratio0.058
Piotroski F Score6.00
Altman Z Score19.94
Sloan Ratio-0.102
Peter Lynch Fair Value0


CORT - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Poor Score of 28.05
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 523529 K 11.99 % 8.42 %
Gross Profit 515898 K 11.97 % 8.05 %
EBITDA 122679 K 21.54 % 8.29 %
Net Profit 117397 K 9.78 % 12.25 %
EPS 1.06 1.71 % NA


CORT - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 94.64
   Altman Z Score of 19.17 suggests good Stability
   Paid More Than 50% of Debt, Heading towards debt free
   Debt to equity ratio has decreased and is lowest in last three years
   Cash ratio of 3.52
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0003 -86.92 % 0.0001
Cash Ratio 3.52 -40.83 %
Quick Ratio 4.31 -36.58 % 5.10
Shareholders Equity 81.53 -5.22 %
Debt to EBITDA 0.0016 -83.16 %


Historical Valuation Ratios of Corcept Therapeutics Inc.

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Corcept Therapeutics Inc.

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Corcept Therapeutics Inc.

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Corcept Therapeutics Inc.

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)